Is domperidone safe and appropriate for treating gastroparesis?

Domperidone for Gastroparesis: Not Recommended as First-Line

The 2025 AGA guidelines suggest against using domperidone as first-line treatment for gastroparesis, though it can be a reasonable second-line option for select patients who cannot tolerate or have failed metoclopramide, particularly those with neurologic side effects or movement disorders like Parkinson's disease. 1

Key Recommendation Details

The AGA guideline provides a conditional recommendation against first-line use based on very low-quality evidence 1. However, this doesn't mean domperidone is unsafe or ineffective—rather, it should be reserved for specific clinical scenarios after shared decision-making.

When Domperidone May Be Appropriate

Domperidone is particularly useful for:

• Patients who developed neurologic adverse effects with metoclopramide (tardive dyskinesia, extrapyramidal symptoms) 1
• Patients with Parkinson's disease or other movement disorders where metoclopramide would be contraindicated 1, 2
• Patients declining metoclopramide due to concerns about its FDA black box warning for tardive dyskinesia 1
• Patients who value symptom improvement (especially nausea, vomiting, early satiety) over potential cardiac risks 1

Efficacy Evidence

Research demonstrates domperidone can be effective:

• In a large single-center cohort of 827 patients, 36% continued treatment for an average of 7.6 years with patients reporting being "moderately better" 3
• 69% of patients reported symptom improvement in another cohort, with particular benefit for postprandial fullness, nausea, vomiting, and stomach fullness 4
• Improvements typically occur within 3 days of starting treatment and are maintained throughout therapy 5
• Long-term studies show sustained benefit with 87% reduction in gastroparesis symptom scores and decreased hospitalizations 6

Critical Safety Considerations and Monitoring

Pre-Treatment Requirements

Before starting domperidone, you must obtain 1:

• Serum potassium level
• Serum magnesium level
• Baseline ECG with QTc interval measurement

Ongoing Monitoring

While on domperidone 1:

• Reassess efficacy at 4-8 weeks to determine if treatment should continue
• Monitor serum potassium, magnesium, and ECG QTc interval regularly throughout treatment
• Watch for cardiac symptoms (palpitations, chest pain)

Common Side Effects

In clinical studies, side effects occurred in approximately 12-38% of patients 4, 3:

• Cardiac: Palpitations (most common), QTc prolongation, chest pain
• Neurologic: Headache, dizziness
• Gastrointestinal: Diarrhea
• Endocrine: Lactation, breast tenderness, menstrual changes (due to prolactin elevation)
• Serious QTc prolongation requiring discontinuation occurred in about 9.5% of patients on high doses 7

Major Practical Barriers

FDA Status in the United States

Domperidone is NOT FDA-approved for human use in the US 1, 8. Prescribing requires:

• An expanded access investigational new drug (IND) application from the FDA
• Important: The current supplier for the FDA IND program is exiting the business and will no longer supply domperidone 1

This means availability in the US is severely limited or potentially ending, making this a critical consideration for treatment planning.

Dosing

Standard dosing is 10 mg three to four times daily (30-40 mg/day), though some patients may require up to 120 mg/day 7, 4. Average effective dose in long-term studies was 36 mg/day 3.

Clinical Decision Algorithm

1. First-line: Use metoclopramide (unless contraindicated by movement disorders)
2. If metoclopramide fails or causes neurologic side effects: Consider domperidone IF:
   • Patient has no baseline QTc prolongation
   • Electrolytes are normal
   • Patient understands cardiac monitoring requirements
   • You can obtain FDA IND approval (currently uncertain due to supply issues)
3. If domperidone unavailable or contraindicated: Consider prucalopride (especially for idiopathic gastroparesis) or erythromycin 1

Bottom Line

While domperidone demonstrates good efficacy and tolerability in research studies with long-term benefit in select patients 3, 6, its role is limited by lack of FDA approval, supply chain issues, and cardiac safety concerns requiring intensive monitoring. It should be reserved as a second-line agent for patients who cannot use metoclopramide, with careful patient selection and mandatory cardiac monitoring throughout treatment.